OBJECTIVE: To investigate the clinical significance of the free-to-total prostate-specific antigen ratio (f/tPSA) and PSA density (PSAD) for @entity263 detection in @entity1 with intermediate tPSA levels (4-10 ng/ml). To establish a cutoff to discriminate between benign @entity4623 (BPH) and @entity263 (CaP), avoiding unnecessary biopsies. METHODS: This prospective study included 136 @entity1 , aged between 54 and 85 (mean 70.6) years old. Urinary tract symptoms were present in these patients. Serum samples were obtained to measure tPSA, fPSA, and f/tPSA; digital rectal examination and transrectal ultrasound eight-sector biopsies were performed. Prostate volume was measured and PSAD calculated. The pathologic study, carried out in 113 @entity1 , showed 82 with BPH and 31 with @entity263 in various stages. RESULTS: There were no significant differences between @entity1 with BPH and CaP when comparing tPSA, fPSA, f/tPSA or digital rectal examination. PSAD and prostate volume were significantly different in @entity1 with BPH and CaP. With a sensitivity of 94% (78.5-99), the f/tPSA cutoff was 0.28 with a 11% (5.2-19.8) specificity. With a sensitivity of 96.2% (80.3-99.4) cutoff for PSAD was 0.109 and specificity 25% (15.5-36.6). CONCLUSIONS: In @entity1 whose tPSA level is between 4 and 10 ng/ml, f/tPSA has no advantages over tPSA measurement for early detection of @entity263 . DPSA can improve specificities, without compromising the detection of CaP.

[Usefulness of free/total PSA ratio and PSA density in distinguishing benign prostatic hypertrophy from XXXX ].

@entity1 :: ('9606', 'Species') :: ['men', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity4623 :: ('MESH:D011469', 'Disease') :: ['prostatic disease']
@entity263 :: (MESH:D011471,Disease) :: ['prostatic cancer']
